Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5982
    -0.0024 (-0.39%)
     
  • NZD/EUR

    0.5537
    -0.0006 (-0.11%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    82.57
    +1.22 (+1.50%)
     
  • GOLD

    2,234.60
    +21.90 (+0.99%)
     
  • NASDAQ

    18,277.53
    -3.31 (-0.02%)
     
  • FTSE

    7,965.89
    +33.91 (+0.43%)
     
  • Dow Jones

    39,777.49
    +17.41 (+0.04%)
     
  • DAX

    18,503.19
    +26.10 (+0.14%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • NZD/JPY

    90.4110
    -0.3690 (-0.41%)
     

Illumina (ILMN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Illumina (ILMN) reported $1.09 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 11.1%. EPS of $0.08 for the same period compares to $1.07 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $1.06 billion, representing a surprise of +2.42%. The company delivered an EPS surprise of +300.00%, with the consensus EPS estimate being $0.02.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Illumina performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- Product revenue: $922 million compared to the $903.98 million average estimate based on six analysts. The reported number represents a change of -13.8% year over year.

  • Revenue- GRAIL: $20 million compared to the $18.67 million average estimate based on six analysts.

  • Revenue- Core Illumina: $1.08 billion compared to the $1.07 billion average estimate based on six analysts.

  • Revenue- Service and other revenue: $165 million versus $148.34 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +7.8% change.

  • Revenue- Product revenue- Instruments: $160 million versus $148.17 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -26.6% change.

  • Revenue- Product revenue- Consumable: $770 million compared to the $749.91 million average estimate based on six analysts. The reported number represents a change of -10.4% year over year.

  • Revenue- Sequencing- Total: $965 million versus the five-analyst average estimate of $905.87 million. The reported number represents a year-over-year change of -12.8%.

  • Revenue- Sequencing- Consumables: $692 million compared to the $667.56 million average estimate based on five analysts. The reported number represents a change of -11.7% year over year.

  • Revenue- Microarrays- Total: $111 million versus $117.97 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -2.6% change.

  • Revenue- Microarrays- Instruments: $6 million versus $4.88 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a 0% change.

  • Revenue- Microarrays- Consumables: $78 million compared to the $76.90 million average estimate based on five analysts. The reported number represents a change of +4% year over year.

  • Revenue- Sequencing- Instruments: $154 million versus the five-analyst average estimate of $141.12 million. The reported number represents a year-over-year change of -27.4%.

View all Key Company Metrics for Illumina here>>>

Shares of Illumina have returned +5.2% over the past month versus the Zacks S&P 500 composite's +4.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Illumina, Inc. (ILMN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research